Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Shares Issued (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Shares Issued data on record, last reported at -$14.6 million in Q4 2025.

  • For Q4 2025, Shares Issued fell 101.53% year-over-year to -$14.6 million; the TTM value through Sep 2025 reached $966.7 million, up 140.89%, while the annual FY2024 figure was $985.0 million, 166.54% up from the prior year.
  • Shares Issued reached -$14.6 million in Q4 2025 per CRNX's latest filing, down from $3.1 million in the prior quarter.
  • Across five years, Shares Issued topped out at $952.2 million in Q4 2024 and bottomed at -$360.5 million in Q3 2024.
  • Average Shares Issued over 5 years is $90.4 million, with a median of $1.8 million recorded in 2022.
  • Peak YoY movement for Shares Issued: crashed 111457.81% in 2021, then skyrocketed 320280.0% in 2023.
  • A 5-year view of Shares Issued shows it stood at $248.3 million in 2021, then crashed by 99.95% to $115000.0 in 2022, then surged by 320280.0% to $368.4 million in 2023, then surged by 158.43% to $952.2 million in 2024, then plummeted by 101.53% to -$14.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were -$14.6 million in Q4 2025, $3.1 million in Q3 2025, and $11.5 million in Q2 2025.